Domperidone API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals

 

Domperidone API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals

1. Introduction

Domperidone is a synthetic pharmaceutical compound belonging to the dopamine D2-receptor antagonist class. It is primarily used in selected medicines for the management of nausea and vomiting. It also has prokinetic properties, which means it can influence the movement of food through the upper gastrointestinal tract.

Domperidone acts mainly on peripheral dopamine receptors, including receptors involved in gastrointestinal movement and the regulation of nausea and vomiting. By blocking dopamine D2 receptors, it can improve gastric motility and produce an antiemetic effect.

In pharmaceutical manufacturing, domperidone maleate is an important salt form used in oral tablet preparations. The free-base form is also relevant to pharmaceutical development and certain formulations. These forms have different molecular weights, CAS numbers, and specifications.

For pharmaceutical manufacturers, selecting the correct chemical form and verifying assay, related substances, residual solvents, and applicable pharmacopoeial requirements are essential quality considerations.

Swapnroop Drugs & Pharmaceuticals welcomes pharmaceutical-sector product enquiries and sourcing discussions. Product grade, availability, specifications, and supporting documentation should be confirmed for each specific requirement.

2. What Is Domperidone API?

Domperidone is a synthetic dopamine antagonist with antiemetic and gastroprokinetic properties. It belongs to the benzimidazolone and heteroarylpiperidine chemical groups.

Its principal pharmacological activity involves blocking dopamine D2 receptors. This action can influence gastrointestinal movement and reduce nausea and vomiting.

Domperidone is used in selected pharmaceutical formulations for:

  • Symptomatic relief of nausea and vomiting

  • Selected gastrointestinal motility-related conditions, where authorised

  • Oral antiemetic preparations

  • Pharmaceutical combination and formulation research

The most commonly referenced salt form in tablet products is domperidone maleate, also known as domperidone monomaleate.

Key characteristics

  • Product name: Domperidone

  • Common pharmaceutical salt: Domperidone maleate

  • CAS number of free base: 57808-66-9

  • CAS number of maleate: 83898-65-1

  • Pharmacological class: Dopamine D2-receptor antagonist

  • Therapeutic category: Antiemetic

  • Chemical class: Benzimidazolone derivative

  • Main pharmacological action: Antiemetic and gastroprokinetic

  • Common dosage form: Oral tablets

3. Domperidone API – Chemical Information

Domperidone and domperidone maleate are related but chemically distinct forms. The maleate salt contains one molecule of maleic acid for each molecule of domperidone.

ParameterDomperidone Free BaseDomperidone Maleate
Product NameDomperidoneDomperidone Maleate
CAS Number57808-66-983898-65-1
Molecular FormulaC₂₂H₂₄ClN₅O₂C₂₂H₂₄ClN₅O₂·C₄H₄O₄
Combined FormulaC₂₂H₂₄ClN₅O₂C₂₆H₂₈ClN₅O₆
Molecular Weight425.91 g/mol541.98 g/mol
Chemical CategoryDopamine antagonistMaleate salt of domperidone
Pharmacological ClassAntiemeticAntiemetic
Therapeutic ApplicationNausea and vomiting managementNausea and vomiting management

Important: The article primarily focuses on domperidone maleate. Its molecular weight of approximately 541.98 g/mol must not be confused with the free-base molecular weight of approximately 425.91 g/mol. Assay calculations and product specifications should identify the exact form and basis of calculation.

4. Chemical Structure and Properties of Domperidone

Domperidone has a complex organic molecular structure containing two benzimidazolone-related ring systems connected through a propyl chain and a piperidine ring.

Its structure includes:

  • A chlorine-substituted aromatic ring

  • Benzimidazolone ring systems

  • A piperidine ring

  • A propyl linker

  • Nitrogen-containing heterocyclic groups

  • Carbonyl functional groups

These structural features contribute to the compound's interaction with dopamine receptors.

Important chemical characteristics

1. Benzimidazolone structure

Domperidone contains benzimidazolone-related structural units that contribute to its molecular identity and physicochemical properties.

2. Piperidine ring

The piperidine component is connected to the molecular framework through a propyl linker and contributes to the compound's chemical structure.

3. Chlorine substitution

A chlorine atom is present on one of the aromatic ring systems.

4. Maleate salt formation

Domperidone maleate is formed through association of domperidone with maleic acid. The salt has a different molecular weight and chemical composition from the free base.

5. Solubility characteristics

The free base and maleate salt have different physicochemical characteristics. Solubility should be assessed using the actual chemical form and the test conditions specified in the applicable product specification.

5. Mechanism of Action of Domperidone

Domperidone acts primarily by blocking dopamine D2 receptors.

Dopamine is a neurotransmitter involved in several physiological processes, including gastrointestinal regulation and the control of nausea and vomiting.

By blocking selected dopamine receptors, domperidone produces antiemetic and gastroprokinetic effects.

5.1 Peripheral Dopamine D2-Receptor Antagonism

Domperidone blocks dopamine D2 receptors, particularly those involved in gastrointestinal regulation.

This action reduces dopamine-mediated inhibition of gastrointestinal movement and contributes to its prokinetic properties.

5.2 Gastroprokinetic Activity

Domperidone can improve gastric motility and promote gastric emptying.

Its effects are associated with:

  • Increased gastric peristalsis

  • Improved gastric emptying

  • Changes in upper gastrointestinal motility

  • Modulation of gastrointestinal coordination

5.3 Antiemetic Activity

Domperidone also acts on dopamine receptors associated with the chemoreceptor trigger zone, an area involved in the regulation of nausea and vomiting.

By blocking dopamine-mediated signalling in this pathway, domperidone can help reduce nausea and vomiting.

5.4 Prolactin Release

Dopamine normally inhibits prolactin secretion from the pituitary gland. Domperidone's dopamine-receptor blocking activity can therefore increase prolactin levels.

This effect is also associated with certain endocrine-related adverse effects.

6. Pharmaceutical Applications of Domperidone API

Domperidone is used in selected pharmaceutical preparations for gastrointestinal and antiemetic applications.

6.1 Nausea and Vomiting

Domperidone is used in certain markets for the short-term symptomatic relief of nausea and vomiting.

Its antiemetic activity is associated with dopamine D2-receptor antagonism.

The approved indications depend on the country, product label, and applicable regulatory restrictions.

6.2 Gastrointestinal Motility

Domperidone has gastroprokinetic properties and may be used in selected settings involving delayed gastric emptying or upper gastrointestinal motility symptoms, where permitted by local product authorisation.

However, regulatory authorities have restricted some previously promoted indications because the available benefit-risk evidence does not support unrestricted use.

6.3 Oral Antiemetic Formulations

Domperidone maleate is used in oral pharmaceutical formulations, particularly tablet preparations.

These products are designed to provide a controlled quantity of the active pharmaceutical ingredient in accordance with the approved product specification.

6.4 Pharmaceutical Research

Domperidone may be relevant to research involving:

  • Dopamine receptor antagonism

  • Gastrointestinal pharmacology

  • Antiemetic formulation development

  • Drug-excipient compatibility

  • Analytical method development

  • Stability evaluation

7. Pharmaceutical Dosage Forms Containing Domperidone

Domperidone has been incorporated into different pharmaceutical dosage forms depending on the market and product authorisation.

Dosage FormGeneral Application
TabletsOral antiemetic preparations
Oral SuspensionsSelected liquid formulations
Oral SolutionsSelected formulations where authorised
Combination ProductsSelected products containing additional active ingredients

The free base and maleate salt may be used differently depending on formulation requirements.

Manufacturers must confirm the intended active form, equivalent active-moiety quantity, and applicable finished-product specification.

8. Manufacturing and Processing Considerations

Domperidone maleate is a synthetic pharmaceutical compound. Its manufacturing involves controlled chemical synthesis, purification, salt formation, isolation, and quality evaluation.

The actual manufacturing route depends on the validated process and approved manufacturing controls.

8.1 Starting Material Qualification

Starting materials should be assessed before use.

Important considerations include:

  • Chemical identity

  • Purity

  • Impurity profile

  • Supplier qualification

  • Batch traceability

  • Compliance with the applicable specification

8.2 Chemical Synthesis

The manufacturing process involves controlled chemical transformations to produce the domperidone molecular structure.

Process controls are important for maintaining the intended molecular identity and limiting unwanted impurities.

8.3 Purification

Purification operations help remove unreacted starting materials, intermediates, and process-related impurities.

Appropriate purification controls are necessary to achieve the required material quality.

8.4 Maleate Salt Formation

The domperidone free-base compound is converted into its maleate salt using maleic acid under controlled processing conditions.

Salt formation must be controlled to ensure the correct stoichiometric form and product quality.

8.5 Crystallisation and Isolation

Crystallisation and isolation operations are used to obtain the final solid material.

The process should be controlled to maintain appropriate physical characteristics and batch consistency.

8.6 Drying and Packaging

The material is dried and packaged according to the approved manufacturing process.

Packaging should protect the API from contamination and unsuitable environmental exposure.

Note: This is a general pharmaceutical manufacturing overview, not a validated manufacturing procedure or a claim regarding SDP's manufacturing capabilities.

9. Quality Control and Testing of Domperidone Maleate

Quality control is essential for ensuring that domperidone maleate meets the applicable pharmaceutical specification.

A suitable testing programme should evaluate chemical identity, assay, impurities, water-related parameters, and other relevant quality attributes.

9.1 Identification Testing

Identification tests confirm that the material corresponds to domperidone maleate.

Possible approaches include:

  • Infrared spectroscopy

  • Chromatographic identification

  • Other applicable pharmacopoeial identification tests

9.2 Assay Testing

Assay testing determines the quantity of domperidone maleate present in the material.

The British Pharmacopoeia and European Pharmacopoeia provide reference standards for domperidone maleate.

The assay method and acceptance criteria should follow the applicable current monograph and approved product specification.

9.3 Related Substances

Related-substance testing evaluates impurities associated with synthesis, processing, or degradation.

Chromatographic methods may be used to separate and evaluate specified and unspecified impurities.

9.4 Loss on Drying

Loss on drying may be used to assess moisture and other volatile components, depending on the applicable specification.

9.5 Sulphated Ash

Sulphated ash testing may be used to evaluate inorganic residue, where required by the applicable monograph.

9.6 Residual Solvents

Residual solvent testing may be required depending on the manufacturing process and relevant regulatory requirements.

9.7 Appearance

Visual inspection helps identify unexpected changes in colour, physical condition, or visible contamination.

9.8 Packaging Integrity

Packaging should be inspected to confirm:

  • Container integrity

  • Correct closure

  • Appropriate labelling

  • Batch identification

  • Protection against contamination

10. Analytical Methods Used for Domperidone API

Several analytical techniques may be used to evaluate domperidone maleate.

Analytical MethodPurpose
HPLCAssay and related-substances analysis
FTIR SpectroscopyChemical identification
UV-Visible SpectroscopySelected quantitative analytical applications
Gas ChromatographyResidual solvent analysis, where applicable
Karl Fischer TitrationWater-content determination, where specified
Loss on DryingEvaluation of moisture and volatile matter
Sulphated AshEvaluation of inorganic residue
Visual ExaminationAppearance and physical quality assessment

The actual testing programme should be based on the applicable pharmacopoeial monograph, validated methods, and approved product specification.

11. Storage and Handling of Domperidone Maleate

Proper storage and handling help maintain the quality and integrity of domperidone maleate.

The storage conditions should follow the applicable product specification and supporting stability data.

Storage considerations

  • Use suitable, well-closed containers.

  • Protect the material from light where required by the applicable specification.

  • Prevent contamination during storage and sampling.

  • Maintain appropriate warehouse conditions.

  • Follow the manufacturer's storage recommendations.

  • Maintain batch identification and traceability.

  • Use suitable packaging materials.

Handling precautions

Personnel handling domperidone maleate should:

  • Consult the current Safety Data Sheet.

  • Use suitable protective gloves.

  • Wear appropriate eye protection.

  • Avoid unnecessary dust generation.

  • Prevent accidental ingestion and direct exposure.

  • Follow workplace hygiene procedures.

  • Use approved sampling and dispensing controls.

12. Safety and Regulatory Considerations

Domperidone has important cardiac safety considerations that must be addressed during pharmaceutical development, product labelling, and clinical use.

12.1 QT Interval Prolongation

Domperidone has been associated with QT interval prolongation, a change in the heart's electrical activity that can increase the risk of serious cardiac arrhythmias.

12.2 Ventricular Arrhythmias

Serious cardiac events, including ventricular arrhythmias and sudden cardiac death, have been reported in association with domperidone use.

Risk may be higher in certain patient groups and when domperidone is used with medicines that increase cardiac risk.

12.3 Risk Factors

Regulatory reviews have identified particular concerns involving:

  • Older patients, especially those over 60 years

  • Higher daily doses

  • Existing cardiac conditions

  • Concomitant use of QT-prolonging medicines

  • Use with strong CYP3A4 inhibitors

12.4 Regulatory Restrictions

The European Medicines Agency reviewed domperidone-containing medicines and recommended restrictions to reduce cardiac risk.

The EU review restricted authorised use primarily to relief of nausea and vomiting, with dose and duration limitations. The maximum treatment duration is generally recommended not to exceed one week under the reviewed guidance.

The exact restrictions differ between countries and must be checked against the current local product authorisation.

12.5 US Regulatory Status

The US FDA states that domperidone is not approved for human use in the United States. The agency has also warned about serious cardiac adverse events associated with its use, including QT prolongation, cardiac arrest, and sudden death.

12.6 Regulatory Considerations for Manufacturers

Pharmaceutical manufacturers should evaluate:

  • Applicable national marketing authorisation

  • GMP requirements

  • API identity and impurity controls

  • Validated analytical methods

  • Stability data

  • Finished-product safety information

  • Packaging and labelling requirements

  • Regulatory pharmacovigilance obligations

Product registration and commercial use must follow the requirements of the intended market.

13. Difference Between Domperidone and Domperidone Maleate

Domperidone and domperidone maleate are related chemical forms, but they have different molecular compositions and molecular weights.

ParameterDomperidoneDomperidone Maleate
Chemical FormFree baseMaleate salt
CAS Number57808-66-983898-65-1
Molecular FormulaC₂₂H₂₄ClN₅O₂C₂₂H₂₄ClN₅O₂·C₄H₄O₄
Molecular Weight425.91 g/mol541.98 g/mol
Common Pharmaceutical ContextFree-base formulations and developmentCommon oral tablet salt form
Active MoietyDomperidoneDomperidone

The active moiety is domperidone in both forms. However, the quantity of maleate salt required to provide a specified amount of domperidone differs from the free-base quantity.

Manufacturers must use the correct salt-to-active-moiety conversion when calculating formulation quantities and labelling strengths.

14. Pharmaceutical Procurement Considerations

Pharmaceutical manufacturers and procurement teams should evaluate several factors before sourcing domperidone maleate.

14.1 Confirm the Chemical Form

Specify whether the requirement is for domperidone free base or domperidone maleate.

14.2 Confirm the Applicable Grade

Identify the required pharmaceutical grade and applicable pharmacopoeial standard, such as BP or Ph. Eur., where relevant.

14.3 Review the Certificate of Analysis

A batch-specific CoA should include actual test results, analytical methods, and acceptance criteria.

14.4 Evaluate Impurity Controls

Review related substances, residual solvents, and other relevant process-related impurities.

14.5 Confirm Assay Basis

Verify whether the assay is expressed as domperidone maleate or calculated as domperidone active moiety.

14.6 Review Supplier Documentation

Depending on the intended application, buyers may request:

  • Batch-specific Certificate of Analysis

  • Product specification

  • Safety Data Sheet

  • Manufacturing and testing information

  • Stability data

  • Relevant compliance declarations

  • Packaging information

14.7 Confirm Regulatory Suitability

Verify that the intended product and use comply with the regulatory requirements of the destination market.

15. Domperidone API Market and Pharmaceutical Industry Relevance

Domperidone has an established role in selected antiemetic and gastrointestinal pharmaceutical products.

Its dopamine-receptor antagonist activity makes it relevant to pharmaceutical formulations intended for nausea and vomiting management.

Important industry considerations include:

  • Consistent chemical quality

  • Correct maleate salt identification

  • Accurate assay calculations

  • Related-substance control

  • Reliable analytical testing

  • Formulation compatibility

  • Stability assessment

  • Regulatory compliance

  • Complete batch documentation

Because of cardiac safety concerns and country-specific restrictions, pharmaceutical manufacturers must evaluate the regulatory status and approved indications of domperidone-containing products in each target market.

16. Domperidone API Enquiries – Swapnroop Drugs & Pharmaceuticals

Swapnroop Drugs & Pharmaceuticals welcomes product-related business enquiries from pharmaceutical manufacturers, formulation developers, distributors, and procurement professionals.

For a Domperidone API enquiry, buyers should specify:

  • Product name: Domperidone Maleate

  • CAS number: 83898-65-1

  • Molecular formula: C₂₆H₂₈ClN₅O₆

  • Molecular weight: 541.98 g/mol

  • Required pharmaceutical grade

  • Applicable pharmacopoeial specification

  • Required quantity

  • Intended dosage form

  • Documentation requirements

  • Destination market

Product identity, availability, grade, documentation, and regulatory suitability should be confirmed directly before any purchase commitment.

Contact Swapnroop Drugs & Pharmaceuticals for product-related business enquiries and sourcing discussions.

17. Frequently Asked Questions (FAQs)

Q1. What is Domperidone API?

Domperidone is a synthetic dopamine D2-receptor antagonist used in selected pharmaceutical products for nausea and vomiting management. It also has gastroprokinetic properties.

Q2. What is the CAS number of Domperidone?

The CAS number of domperidone free base is 57808-66-9.

Q3. What is the CAS number of Domperidone Maleate?

The CAS number of domperidone maleate is 83898-65-1.

Q4. What is the molecular formula of Domperidone Maleate?

The molecular formula is C₂₂H₂₄ClN₅O₂·C₄H₄O₄, also represented as C₂₆H₂₈ClN₅O₆.

Q5. What is the molecular weight of Domperidone Maleate?

Its molecular weight is approximately 541.98 g/mol.

Q6. What is the difference between Domperidone and Domperidone Maleate?

Domperidone is the free-base compound, whereas domperidone maleate is its salt formed with maleic acid. They have different CAS numbers, molecular formulas, and molecular weights.

Q7. How does Domperidone work?

Domperidone blocks dopamine D2 receptors, helping reduce nausea and vomiting and influencing upper gastrointestinal motility.

Q8. What are the pharmaceutical applications of Domperidone?

It is used in selected oral pharmaceutical formulations for symptomatic relief of nausea and vomiting, subject to local regulatory approval.

Q9. What quality tests are important for Domperidone Maleate?

Important tests include identification, assay, related substances, loss on drying, residual solvents where applicable, and other tests required by the applicable specification.

Q10. Why is cardiac safety important for Domperidone?

Domperidone has been associated with QT prolongation, ventricular arrhythmias, and sudden cardiac death. Regulatory authorities have therefore restricted its use in certain markets and patient groups.

Q11. Is Domperidone approved in the United States?

The US FDA states that domperidone is not approved for human use in the United States.

Q12. What documents should be reviewed when sourcing Domperidone API?

Buyers should review a batch-specific Certificate of Analysis, product specification, Safety Data Sheet, manufacturing and testing information, stability data, and relevant regulatory documentation.

Conclusion

Domperidone is a synthetic dopamine D2-receptor antagonist with antiemetic and gastroprokinetic properties. It is used in selected pharmaceutical preparations for the symptomatic management of nausea and vomiting.

Domperidone maleate is an important pharmaceutical salt form used in oral formulations. Correct identification of the free base and maleate salt is essential for product specifications, assay calculations, formulation development, and procurement.

Quality evaluation should address identity, assay, related substances, moisture-related parameters, packaging, and batch documentation. In addition, cardiac safety and market-specific regulatory restrictions must be considered when developing or supplying domperidone-containing products.

Swapnroop Drugs & Pharmaceuticals welcomes product-related business enquiries from pharmaceutical manufacturers, distributors, and procurement professionals. Product grade, availability, documentation, and regulatory suitability should be verified before procurement.

Comments

Popular posts from this blog

🌿 Probiotics IR Pellets – Fast-Acting Gut Health Solution by Swapnroop Drugs & Pharmaceuticals 🌿

🌱 Probiotics EC Pellets – Stabilized Gut Health Powerhouses by Swapnroop Drugs & Pharmaceuticals

Azithromycin Taste-Masked Powder: A Pediatric-Friendly Innovation by Swapnroop Drugs & Pharmaceuticals